RecruitingPhase 2NCT07168902
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension
A Phase 2 Evaluation of the Safety, Ocular Tolerability, and Efficacy of Topical Ophthalmic BL1107 Versus Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension
Sponsor
Bausch & Lomb Incorporated
Enrollment
228 participants
Start Date
Oct 24, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults with Primary Open Angle Glaucoma or Ocular Hypertension
Eligibility
Min Age: 18 Years
Inclusion Criteria1
- Ocular hypertension or primary open-angle glaucoma in each eye
Exclusion Criteria4
- History of orthostatic hypotension
- Any active ocular disease
- Anticipated wearing of contact lenses during study
- Contraindication to pupil dilation
Interventions
DRUGBL1107 Low dose
Dosed twice daily for 28 days.
DRUGBL1107 High dose
Dosed twice daily for 28 days.
DRUGTimolol maleate 0.5%
Dosed twice daily for 28 days.
Locations(8)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07168902
Related Trials
Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications
NCT043545451 location
Transcorneal Electrical Stimulation for the Treatment of Visual Field Defects in Patients With Open-Angle Glaucoma
NCT066829621 location
Alcon Hydrus Stent Implantation - Long Term Follow up After 8 Years
NCT074607911 location
Automated Applanation Tonometry - Updated
NCT072983561 location
Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use
NCT072176781 location